Acadia Pharmaceuticals Inc. (ACAD) Q4 2015 Earnings Results

ACADIA Pharmaceuticals Misses on EPS — Stock Down 7.85%

The earnings report indicates that ACADIA Pharmaceuticals is still facing challenges, particularly with its earnings performance. The stock dropped 7.85% in reaction to the missed EPS expectations. Investors may be concerned about the lack of revenue data and future guidance, which could signal uncertainty about the company's path forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.45	N/A	-20.64%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over the current financial performance. They highlighted the need for continued investment in research and development.

Management acknowledged challenges in achieving profitability.

They emphasized ongoing efforts to enhance product development.

ACADIA Pharmaceuticals Misses on EPS — Stock Down 7.85%

Key numbers

Management commentary

Acadia Pharmaceuticals Inc.

More earnings this week

ACADIA Pharmaceuticals Misses on EPS — Stock Down 7.85%

Key numbers

Management commentary